Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
30 patents granted to the 6 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Q/C Technologies, Inc.’s names, not what it holds today.
Patents granted
30
25 utility, 5 design, 1976 to Dec 31, 2025
Granted in 2025
1
Against 2 in 2024 and 1 in 2023
Applications published
25
since 2001, to Dec 31, 2025
Names they are printed under
6
a former name, a subsidiary, its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals3
Biotechnology2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name6 counted
MyMD Pharmaceuticals, Inc. a former name
named as the applicant on its applications, in US
18 publishedAkers Biosciences, Inc. a former name
US, as the owner printed on each patent
5 publishedMyMD Pharmaceuticals, Inc. a former name
US, as the owner printed on each patent
1 publishedAkers Acquisition Sub, Inc. a subsidiary
US, as the owner printed on each patent
0 publishedQC Technologies its own name
US, as the owner printed on each patent
1 publishedTNF Pharmaceuticals, Inc. a former name
US, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jul 15, 2025 | 12,357,625 | Methods of regulating oxidoreductase activity for treatment of chronic obstructive pulmonary disease (COPD) | Pharmaceuticals | TNF Pharmaceuticals, Inc. |
| Oct 29, 2024 | 12,129,473 | Synthetic cannabinoid compounds for treatment of pain and anxiety | Biotechnology | TNF Pharmaceuticals, Inc. |
| Mar 26, 2024 | 11,938,126 | Method of treating diseases of the visual system | Pharmaceuticals | MyMD Pharmaceuticals, Inc. |
| Apr 18, 2023 | 11,629,355 | Synthetic cannabinoid compounds for treatment of epilepsy, substance addiction and Alzheimer's disease | Biotechnology | MyMD Pharmaceuticals, Inc. |
| Feb 16, 2021 | 10,918,633 | Method of treating coronavirus | Pharmaceuticals | MyMD Pharmaceuticals, Inc. |
| Nov 17, 2020 | 10,835,523 | Method of regulating tumor necrosis factor-alpha (TNF-α) for treating cancers, autoimmune disorders, and other disorders associated with chronic inflammation | Pharmaceuticals | MyMD Pharmaceuticals, Inc. |
| Oct 20, 2020 | 10,806,728 | Pharmaceutical salts of isomyosmine and pharmaceutical compositions containing same | Pharmaceuticals | MyMD Pharmaceuticals, Inc. |
| Sep 29, 2020 | 10,786,493 | Method of treating viral infections | Pharmaceuticals | MyMD Pharmaceuticals, Inc. |
| Jul 28, 2020 | 10,722,506 | Method of treating multiple sclerosis | Pharmaceuticals | MyMD Pharmaceuticals, Inc. |
| Mar 17, 2020 | 10,588,899 | Methods of treating diabetes | Pharmaceuticals | MyMD Pharmaceuticals, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jul 6, 2023 | 2023/0212597 | Synthetic Cannabinoid Compounds for Treatment of Pain and Anxiety | Biotechnology | MyMD Pharmaceuticals, Inc. · patent 12,129,473 granted from it |
| Oct 27, 2022 | 2022/0339147 | Method of Treating Diseases of the Visual System | Pharmaceuticals | MyMD Pharmaceuticals, Inc. · patent 11,938,126 granted from it |
| Apr 15, 2021 | 2021/0106578 | METHOD OF TREATING DISORDERS ASSOCIATED WITH CHRONIC INFLAMMATION | Pharmaceuticals | MyMD Pharmaceuticals, Inc. · patent 11,096,933 granted from it |
| Oct 29, 2020 | 2020/0338061 | Methods of Regulating Oxidoreductase Activity for Treatment of Inflammation and Age-Related Disorders | Pharmaceuticals | MyMD Pharmaceuticals, Inc. · patent 11,219,620 granted from it |
| Jul 9, 2020 | 2020/0215045 | Method of Treating Substance Addictions | Pharmaceuticals | MyMD Pharmaceuticals, Inc. · patent 11,331,310 granted from it |
| Jun 11, 2020 | 2020/0179367 | Method of Treating Coronavirus | Pharmaceuticals | MyMD Pharmaceuticals, Inc. · patent 10,918,633 granted from it |
| Jun 11, 2020 | 2020/0179366 | METHOD OF TREATING VIRAL INFECTIONS | Pharmaceuticals | MyMD Pharmaceuticals, Inc. · patent 10,786,493 granted from it |
| Jun 11, 2020 | 2020/0179365 | Method of Regulating Tumor Necrosis Factor-alpha (TNF-alpha) for Treating Cancers, Autoimmune Disorders, and Other Disorders Associated with Chronic Inflammation | Pharmaceuticals | MyMD Pharmaceuticals, Inc. · patent 10,835,523 granted from it |
| Apr 2, 2020 | 2020/0101060 | Method of Treating Multiple Sclerosis | Pharmaceuticals | MyMD Pharmaceuticals, Inc. · patent 10,722,506 granted from it |
| Mar 12, 2020 | 2020/0078344 | Methods of Reversing Normal Aging Process And Extending Lifespan | Pharmaceuticals | MyMD Pharmaceuticals, Inc. · patent 11,179,382 granted from it |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.